Beijing Tri Prime Gene Pharmaceutical Co (BJSE:837344) Ending Cash Position : ¥91.6 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Beijing Tri Prime Gene Pharmaceutical Co Ending Cash Position?

Beijing Tri Prime Gene Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2025 was ¥91.6 Mil.

Beijing Tri Prime Gene Pharmaceutical Co's quarterly Ending Cash Position declined from Sep. 2024 (¥125.0 Mil) to Dec. 2024 (¥113.1 Mil) and declined from Dec. 2024 (¥113.1 Mil) to Mar. 2025 (¥91.6 Mil).

Beijing Tri Prime Gene Pharmaceutical Co's annual Ending Cash Position declined from Dec. 2022 (¥225.4 Mil) to Dec. 2023 (¥177.5 Mil) and declined from Dec. 2023 (¥177.5 Mil) to Dec. 2024 (¥113.1 Mil).

Beijing Tri Prime Gene Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Beijing Tri Prime Gene Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tri Prime Gene Pharmaceutical Co Ending Cash Position Chart

Beijing Tri Prime Gene Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

319.30

274.22

225.43

177.51

113.07

Beijing Tri Prime Gene Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															157.13	154.80	124.96	113.07	91.56

Beijing Tri Prime Gene Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Beijing Tri Prime Gene Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	177.507	+	-64.438
	=	113.1

Beijing Tri Prime Gene Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	113.069	+	-21.512
	=	91.6

Beijing Tri Prime Gene Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Beijing Tri Prime Gene Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Tri Prime Gene Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Tri Prime Gene Pharmaceutical Co Ltd (BJSE:837344) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Jinyuan Road, Building 4, Daxing Economic Development Zone, Daxing District, Beijing, CHN, 102600

Website

http://www.triprime.com

Beijing Tri Prime Gene Pharmaceutical Co Ltd is mainly engaged in the research, development, production, and sales of medical biotechnology products including genetic engineering drugs, genetic engineering vaccines, and diagnostic reagents, and engaged in related technical trade and technical consulting services. Its product line comprises Yundex Spray, Yundex Eye Drops, Yundexol Powder Injection, Yundexol Water Injection.

Beijing Tri Prime Gene Pharmaceutical Co Headlines

No Headlines